featured
2017 Top Stories in Metastatic Breast Cancer: The Potential for Immunotherapy in Breast Cancer
Written by
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Nanda R, Chow LQM, Dees EC, et al Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol. 2016;34(21):2460-2467.
- Adams S, Schmid P, Rugo HS, et al. Phase 2 study of pembrolizumab (pembro) monotherapy for previously treated metastatic triple-negative breast cancer (mTNBC): KEYNOTE-086 cohort A. J Clin Oncol 35, 2017 (suppl; abstr 1008).
- Dirix LY, Takacs I, Jerusalem G, et al. Avelumab, an Anti-PD-L1 Antibody, in Patients With Locally Advanced or Metastatic Breast Cancer: A Phase 1b JAVELIN Solid Tumor [published online October 23, 2017]. Breast Cancer Res Treat. doi: 10.1007/s10549-017-4537-5.
- Schmid P, Cruz C, Braiteh FS, et al: Atezolizumab in metastatic TNBC: Long-term clinical outcomes and biomarker analysis. Paper presented at: 2017 AACR Annual Meeting; April 1-April 5, 2017; Washington, DC. Abstract 2986.
-
Tolaney S, Savulsky C, Aktan G, et al. Phase 1b/2 study to evaluate eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer. Paper presented at: 2016 San Antonio Breast Cancer Symposium; December 6-10, 2016; San Antonio, TX. Abstract P5-15-02.
Disclosure statements are available on the authors' profiles: